Metformin promotes anti-tumor immunity in STK11 mutant NSCLC through AXIN1-dependent upregulation of multiple nucleotide metabolites.

ABSTRACT:

Background

Metformin has pleiotropic effects beyond glucose reduction, including tumor inhibition and immune regulation. It enhanced the anti-tumor effects of programmed cell death protein 1 (PD-1) inhibitors in serine/threonine kinase 11 (STK11) mutant non-small cell lung cancer (NSCLC) through an axis inhibition protein 1 (AXIN1)-dependent manner. However, the alterations of tumor metabolism and metabolites upon metformin administration remain unclear.

Methods

We performed untargeted metabolomics using liquid chromatography (LC)-mass spectrometry (MS)/MS system and conducted cell experiments to verify the results of bioinformatics analysis.

Results

According to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database, most metabolites were annotate

SUBMITTER: Wang Z 

PROVIDER: S-EPMC11413838 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature